Affiliate disclosure: The RX Index earns a commission when you sign up with some of the providers mentioned on this page. It does not affect what you pay, and it never determines our rankings or which providers we cover. Read the full disclosure.

Step Therapy for Wegovy: Real Plan Rules, Exception Paths, and How to Appeal a Denial

By The RX Index Editorial Team — The RX Index is a pricing intelligence and comparison resource for GLP-1 telehealth providers.

Published: May 4, 2026

Last verified: May 4, 2026

Sources reviewed: CVS Caremark/Aetna PA with Limit 4774-C P08-2025 v4; Cigna Coverage Policy IP0206; Cigna CNF_684; UnitedHealthcare PA Notifications (commercial and non-formulary CV/MASH); BCBS FEP via CVS Caremark; TRICARE / Express Scripts Wegovy PA form; FDA prescribing information for Wegovy injection and tablets.

Affiliate disclosure: Some links on this page are affiliate links. The RX Index may earn a commission at no extra cost to you. That does not change which official sources we cite, which plan rules we publish, or which provider we recommend for which type of reader.

The Bottom Line in 60 Seconds

Step therapy for Wegovy means your insurance wants proof you completed an earlier step before they pay for Wegovy. That step is usually one of three things: a 3–6 month documented weight-loss program, a trial of a cheaper anti-obesity medication, or a documented reason a cheaper medication is unsafe for you.

The two-sentence catch most people miss: a lot of “step therapy” denial letters are actually about missing paperwork, not a required medication trial. And every fix starts by identifying which of the six rules your plan is actually enforcing.

Wegovy® (semaglutide) is FDA-approved as injection and tablets, with a boxed warning and specific contraindications that should be evaluated by a clinician — this page is editorial guidance, not medical advice. Always work with your prescriber.

Quick Decoder — What Your Denial Probably Means

Wegovy Step Therapy: Decode Your Denial — infographic showing what each denial type means (step therapy required, prior authorization required, benefit exclusion, renewal denied, quantity limit) and what to do next

If your denial says…	It probably means…	Your next move
“Step therapy required”	Try a cheaper drug first OR document why you can't	Get the exact drug list and trial duration in writing
“Prior authorization required”	Paperwork is missing, not necessarily a drug trial	Pull BMI, comorbidity, and weight-program records
“Benefit exclusion”	Plan does not cover weight-loss drugs at all	Check if CV or MASH indication applies; ask HR
“Renewal denied”	You did not meet the continuation rule (often 5% weight loss)	Pull baseline weight + current weight + dose history
“Non-formulary” / “tier exception needed”	Wegovy isn't on the preferred drug list	File a formulary exception, not a step therapy appeal
“Quantity limit”	Dose, refill timing, or supply limit triggered the block	Ask the pharmacy which specific limit fired

Filing the wrong type of appeal is a common reason people lose months. Many letters labeled “step therapy” describe situations that aren't actually a required medication trial.

Take the 60-Second Wegovy Denial Decoder →

What “Step Therapy for Wegovy” Actually Means

Step therapy is your insurer asking you to prove you completed a required step before they cover Wegovy. The step can be a prior medication trial, a documented weight-management program, a documented contraindication, or proof of an FDA-approved indication the plan covers. It is not the same as prior authorization, and it is not the same as a benefit exclusion — and which one you're facing changes everything about your next move.

Insurance companies use step therapy because Wegovy lists at $1,349.02 per month before insurance discounts. Step therapy lets the plan say: “Try something cheaper first, and if it doesn't work, we'll cover Wegovy.”

Step therapy vs. prior authorization vs. benefit exclusion

Prior authorization (PA)Your prescriber needs to submit clinical documentation. No drug trial required, just paperwork.

Step therapyYour plan requires you to try a specific cheaper drug for a specific time period and either lose enough weight on it, stop because of side effects, or document a contraindication.

Benefit exclusionYour plan does not cover weight-loss medications at all. Step therapy paperwork won't fix this.

Renewal thresholdYou were approved before, but they want proof you lost at least 5% of your body weight to keep covering it.

Quantity limitThe plan limits dose, refill timing, or supply.

Most “Step Therapy” Denials Aren't Really Medication Step Therapy: The 6 Things Plans Actually Require

When we read public PA criteria across the major insurers, we found six different things plans bundle under the “step therapy” banner. Knowing which one your plan is asking for is the difference between getting Wegovy in two weeks and waiting six months.

The 3–6 month documented weight management program

This is what Aetna's public Wegovy PA Policy 4774-C asks for. Coverage requires participation in a comprehensive weight-management program with behavioral modification, reduced-calorie diet, increased physical activity, and continuing follow-up for at least 6 months before drug therapy. Cigna's public weight-loss GLP-1 policy (IP0206) asks for at least 3 months of behavioral modification and dietary restriction.

This is the #1 denial reason in patient forums — readers think they need a drug trial; they actually need records of:

Dietitian or weight-loss counselor visits
Structured program participation (Weight Watchers, Noom, hospital-based program)
Doctor visits where weight, diet, and exercise were discussed
Calorie tracking logs and activity logs

The cheaper-medication trial (true step therapy)

This is what most people picture. Your plan asks you to try one (or sometimes more) of these for a set period:

Phentermine (Adipex-P, Lomaira)

Contrave (naltrexone-bupropion)

Qsymia (phentermine-topiramate)

Orlistat (Xenical, OTC Alli)

Saxenda (liraglutide)

TRICARE's current public Wegovy PA form spells this out clearly: it asks if the patient tried 3 months of generic phentermine-class drugs and failed to lose 5% of baseline weight, or whether the patient has a contraindication or adverse reaction documented. True cheaper-drug step therapy is less common in commercial plans than people assume.

The BMI + comorbidity proof

Every public Wegovy PA criteria we reviewed requires:

BMI ≥ 30 (obesity), OR
BMI ≥ 27 plus at least one weight-related health condition

Common qualifying comorbidities: type 2 diabetes, high blood pressure, high cholesterol, sleep apnea, established cardiovascular disease. Wrong or incomplete ICD-10 coding causes denials labeled “step therapy” or “not medically necessary” even when the patient clearly qualifies.

The 5% renewal threshold

This blocks people who already got Wegovy approved before. Most plans (Aetna, Cigna, UnitedHealthcare, BCBS FEP, TRICARE — every public policy we reviewed) require proof the patient lost at least 5% of baseline body weight (or maintained that loss) to renew coverage.

If you're being denied at renewal, gather: your starting weight, your most recent weight, doses taken and dates, and any plateau explanation from your prescriber. If you didn't hit 5%, you can still appeal — the strongest appeals show ongoing benefit beyond weight (improved A1c, lower blood pressure, better sleep).

The benefit exclusion

This is the one no amount of step therapy paperwork will fix. Some plans simply do not cover weight-loss medications at all. Words that signal exclusion: “not a covered benefit,” “weight management excluded,” “obesity drug exclusion.”

Three real options:

Check if a different FDA-approved indication applies. Wegovy is approved for cardiovascular risk reduction and for MASH (liver condition) with fibrosis.
Talk to HR. For self-funded employer plans, the employer plan sponsor controls the benefit design.
Use a self-pay path. NovoCare's published self-pay pricing for the Wegovy pen starts at $199/month for the first two monthly fills (intro offer through June 30, 2026), then $349/month. The Wegovy pill is $149/month for 1.5 mg and 4 mg through August 31, 2026.

The quantity limit

Less common, but real: your plan may limit Wegovy refills to a specific dose, frequency, or supply window. If your pharmacy says “fill too soon” or “quantity limit,” that's not step therapy. Ask the pharmacy or PBM what specific limit fired and have your prescriber file an override.

Do You Have to Try Phentermine Before Wegovy?

Sometimes, but not on every plan. In the public commercial policies we verified for Aetna, Cigna, UnitedHealthcare, and BCBS FEP, the recurring requirements were more often lifestyle program documentation, BMI/comorbidity proof, and renewal weight-loss thresholds — not a cheaper-drug fail-first. TRICARE's current public Wegovy form does require a 3-month trial of generic phentermine-class drugs (or documented contraindication or adverse reaction).

Phentermine (and similar stimulant-class drugs) carries real safety considerations. Your prescriber decides whether it's appropriate. Reasons a clinician might document phentermine as contraindicated or inappropriate include cardiovascular conditions, uncontrolled hypertension, hyperthyroidism, glaucoma, MAOI use, history of substance use disorder, or a previous adverse reaction.

If a phentermine trial was required and your prescriber agrees it's appropriate, the documentation needs:

Medication tried, start and stop dates, dose if known, duration
Outcome (specifically: weight change at the end of the trial)
Adverse reaction or reason stopped, if applicable
Contraindication if applicable
Why Wegovy is the right next step

Verified Payer-by-Payer Requirements: What the Major Insurers Actually Ask For

Verified as of May 4, 2026. Plan rules change. Confirm against your specific plan's documents or denial letter before you act.

Plan / Source policy	True medication fail-first?	What the verified criteria say	Renewal rule	Best next move
Aetna (CVS Caremark PA 4774-C, P08-2025 v4)	Not in the public Wegovy policy	6-month comprehensive weight-management program (behavioral modification + reduced-calorie diet + increased activity + follow-up), BMI ≥30 or ≥27 with comorbidity. Initial approval: typically 8 months (adult injection, weight mgmt), 6 months (tablets), 7 months (pediatric), 12 months (CV/MASH).	12-month continuation with ≥5% baseline weight loss + continued program participation	Most “step therapy” Aetna denials = missing program documentation. Attach detailed program records.
Cigna / Evernorth (IP0206 + CNF_684)	Generally no in public Wegovy section	Initial adult Wegovy weight-loss approval 8 months (IP0206), 7 months (CNF_684 — verify which applies). Requires 3+ months behavioral modification + dietary restriction, BMI ≥30 or ≥27 with comorbidity.	1 year continuation if currently on Wegovy, ≥5% baseline weight loss, continued behavior modification	Verify the exact Cigna plan policy — self-funded employer plans often differ.
UnitedHealthcare (commercial weight-loss PA)	Sometimes	Coverage only on plans that elected weight-loss product coverage. Initial Wegovy auth is 5 months. BMI ≥30 or ≥27 + comorbidity. Some UHC plans use BMI ≥40 threshold.	≥5% baseline weight loss + lifestyle modification. 12-month continuation.	First confirm whether your UHC plan covers weight-loss meds at all.
UHC non-formulary (CV/MASH-only policy)	No — this is a benefit exclusion path	Weight-loss meds are a benefit exclusion. Wegovy allowed only for established cardiovascular disease (with obesity/overweight) or MASH with fibrosis.	12-month authorization when CV or MASH criteria met	Do NOT file a step therapy appeal. Ask whether CV or MASH indication applies.
BCBS FEP (via CVS Caremark)	Not a cheaper-drug fail-first in public criteria	Requires chronic weight-management diagnosis, BMI criteria, comprehensive weight-management program, no dual GLP-1 therapy, no dual PA weight-loss medication. Initial 6-month approval.	12-month renewal requires ≥5% baseline weight loss or maintained loss	If you're on another GLP-1 or another covered weight-loss med, the dual-therapy rule is the real blocker.
TRICARE (Express Scripts PA form)	Yes — verified	Asks if adult patient tried 3 months of generic phentermine, benzphetamine, diethylpropion, or phendimetrazine and failed to lose 5% baseline weight, OR has documented contraindication or adverse reaction. Initial approval 12 months. TRICARE no longer covers GLP-1s for weight management for TRICARE For Life, direct-care-only, and certain NATO/PFP beneficiaries after Aug 31, 2025.	Annual renewal requires ≥5% baseline weight loss after full dose titration	If a generic stimulant is unsafe for you, document the contraindication directly.
Custom employer / Medicaid / state plans	Plan-specific	Self-funded employer plans on any insurer can layer step therapy not in the public commercial criteria. State Medicaid GLP-1 weight-loss coverage varies and several states have restricted coverage in 2025–2026.	Varies	Don't assume “Aetna covers Wegovy” means your Aetna plan does. Pull your Summary Plan Description.

Insurance paperwork is your bottleneck? Let Ro check your coverage first.

Ro's free GLP-1 Insurance Coverage Checker contacts your insurance plan, identifies eligibility details, and shows whether prior authorization may be required — before you commit to anything. The free coverage checker doesn't submit treatment requests or write prescriptions.

Check Wegovy Coverage Through Ro — Free →

Medication and membership billed separately if you continue with Ro.

Prior Medication History That May Help Your Case

Your past prescription history can strengthen a Wegovy step therapy exception or appeal — but whether it satisfies the requirement depends on your plan's specific criteria. Pull your records regardless — they often shorten what your prescriber has to file.

Medication you may have taken	How it could help your case	What to gather
Ozempic (semaglutide, off-label for weight)	Documents prior GLP-1 exposure and outcome	Pharmacy fill history, dates, doses, A1c if checked, weight at start and stop
Saxenda (liraglutide)	Documents prior GLP-1 weight-management trial	Fill history, dates, doses, weight outcome, side effects if any
Trulicity (dulaglutide)	Documents prior GLP-1 class exposure	Fill history, dates, A1c response, weight response
Rybelsus (oral semaglutide)	Documents prior oral semaglutide exposure	Fill history, dates, doses, outcome
Phentermine (Adipex-P, Lomaira)	Often the named Tier 1 step on plans requiring true step therapy	Dates, dose, duration, weight change, side effects, reason stopped
Contrave	Often a named step on plans requiring true step therapy	Dates, dose, duration, weight change, side effects, reason stopped
Qsymia	Often a named step on plans requiring true step therapy	Dates, dose, duration, weight change, side effects, reason stopped
Orlistat (Xenical, OTC Alli)	Often a named step; OTC Alli purchase records can substantiate	Receipts or pharmacy fill history, duration, side effects, reason stopped

How to pull the records that prove it:

Call every pharmacy you've used in the last 5 years and ask for a complete fill history (CVS, Walgreens, Costco, Walmart, mail-order). Most patient portals have it under “prescription history.”
Note for each prior medication: drug and dose, start and stop dates, why you stopped, any side effects you remember.
Hand this to your prescriber before they file the PA.

What “failed” actually means:

You took it for the required duration (often 3 months) and lost less than 5% of body weight
You couldn't tolerate the side effects — this typically supports an intolerance or adverse-reaction exception
You discovered a contraindication
A serious adverse reaction made you stop

“I forgot to refill” or “it was too expensive” usually doesn't count.

State Step Therapy Override Laws — Does Your State Protect You?

The catch most articles skip: state laws usually apply to state-regulated commercial plans. Self-funded ERISA plans often sit outside state insurance mandates, and Medicaid applicability varies by state.

State	Override law?	Standard response	Emergency	Notable feature
Colorado	Strong protections	Per state rule	Per state rule	One of the strongest patient-protection frameworks
New York	Yes (2026 law)	72 hours	24 hours	Limits step therapy to ≤2 drugs in same therapeutic category; deemed-approval remedy if plan misses deadline
New Jersey	Yes (Jan 1, 2026 reform)	72 hours	24 hours	Newest comprehensive law; expanded guardrails including state Medicaid
California	Yes	72 hours	24 hours (serious jeopardy)	SB 40 (2026) prohibits step therapy specifically for insulin
Texas	Yes (SB 680)	72 hours	24 hours	Required exception process
Illinois	Yes	72 hours	24 hours	Required exception process
New Mexico	Yes	72 hours	24 hours	Required exception process
Indiana, Kansas, Virginia	Yes	72 hours	24 hours	Strong general framework
Georgia, Oklahoma, Wisconsin	Yes (effective 2020+)	72 hours	24 hours	Standard reform package
Washington	Yes (effective 2021)	72 hours	24 hours	Required exception process
States with no reform (~21 states)	Insurer policy controls	Varies	No statutory requirement	About 21 states fall here

The fully-insured vs. self-funded trap

Your employer plan is one of two things:

Fully-insured: your employer buys insurance from a carrier. The carrier accepts financial risk. Your state's insurance laws generally apply, including step therapy reform.
Self-funded: your employer pays claims directly. The carrier just administers the plan. Federal ERISA law applies. Most state step therapy reform laws don't.

About 60% of large employer plans are self-funded. Your insurance card looks the same either way. The phrase to use with HR: “Is our medical plan fully-insured or self-funded for ERISA purposes?”

How to File a Step Therapy Exception Request for Wegovy

A Step Therapy Exception Request is a formal document your prescriber submits asking the insurer to waive the step therapy requirement. It must cite at least one of seven recognized exception categories. Federal Medicare Advantage rules require a 72-hour response. Most state reform laws require similar timelines for state-regulated commercial plans.

The seven recognized exception categories

1. Prior failure

You took it before for the required duration and didn't get adequate response. Pharmacy fill records prove duration; chart notes prove outcome.

2. Contraindication

A medical reason makes the drug unsafe. Your prescriber must determine and document the contraindication — do not self-diagnose.

3. Intolerance / adverse reaction

You tried it and had side effects you couldn't manage. Document the drug, dose, dates, specific reaction, and that you stopped because of it.

4. Expected adverse reaction

Based on your medical history (genetic, prior similar drugs), the prescriber reasonably expects you to have an adverse reaction.

5. Expected non-response

Your clinical history suggests the step drug won't work — for example, you've already failed multiple weight-loss medications in the same class.

6. Currently stable on Wegovy

You're already on Wegovy under a previous insurer or self-pay, and switching would jeopardize your treatment. Critical for renewals after insurance changes.

7. Best clinical interest

Your prescriber documents that the step drug is not in your best interest based on current clinical evidence (cardiovascular indication, established CV disease, MASH, etc.).

Your prescriber's letter — what it needs to include

Patient name, DOB, insurance ID
Diagnosis with ICD-10 codes
Specific FDA-approved Wegovy indication (weight loss, CV risk reduction, or MASH)
Current BMI, height, weight, baseline weight history
Comorbidities with ICD-10 codes
Previous weight-management efforts (program records)
Previous medication trials with specific dates, doses, durations, and outcomes
The specific exception category being claimed (from the seven above)
Clinical risk of delay
Direct request: “I am requesting approval of Wegovy for [patient name] under exception category [#].”
Prescriber's signature, NPI, contact info, and attachments list

Decision path	Typical timeline
State-regulated commercial plan in a reform state	Insurer must respond within the state-specified window (typically 72 hours; 24 hours emergency)
Medicare Advantage	Federal CMS rules require 72-hour standard response
Self-funded employer plan (ERISA)	Plan-specific; ERISA rules generally require ~15 days for pre-service claims
TRICARE	Express Scripts handles per their published timeline

Wegovy Appeal Prep: What to Bring to Your Prescriber — checklist of records to bring (denial letter, insurance card, weight history, comorbidities, pharmacy fill history, weight-management program records, previous weight-loss medications, contraindications, recent labs) and what your prescriber should document for the strongest appeal

How to Appeal a Wegovy Step Therapy Denial

Appealing is worth the effort even though most patients don't try. KFF's analysis of 2024 ACA Marketplace claims found fewer than 1% of denied in-network claims were appealed, and when patients did file internal appeals, insurers upheld 66% of them (meaning roughly 1 in 3 internal appeals succeeded). For Medicare Advantage prior-authorization denials, federal data shows about 80% of appealed PA denials were overturned, with only about 11.5% of PA denials appealed.

Level 1 — Internal appeal

Your prescriber resubmits with new documentation answering the exact denial reason. Most insurers decide within 30 days for pre-service cases.

Level 2 — Peer-to-peer review

Your prescriber gets on the phone with the insurer's medical director. This is where many denials get reversed because the medical director can override on clinical grounds. Prescribers can request peer-to-peer in their initial appeal.

Level 3 — External review

An independent third-party reviewer (not affiliated with your insurer) evaluates the case. Their decision is binding on the insurer. Standard external reviews: 45 days. Expedited: 72 hours.

Level 4 — State DOI complaint

Free, takes 5 minutes online. Triggers regulatory review. Especially powerful for state-regulated commercial plans.

Level 5 — Federal complaint

For ERISA self-funded plans: file with the Employee Benefits Security Administration. For Medicare: file with CMS.

Letter of Medical Necessity — the pattern that works

Paragraph 1 — Patient summary

“I am writing to request approval of Wegovy (semaglutide) for my patient [name], who is a [age]-year-old with [diagnosis] and BMI [#]. Coverage was denied on [date] citing [exact denial reason].”

Paragraph 2 — Why Wegovy specifically

Cite FDA labeling for the indication. Reference the STEP 1 trial (~14.9% mean weight loss at 68 weeks) and the SELECT trial (20% reduction in major adverse cardiovascular events).

Paragraph 3 — Why the step therapy requirement should be waived

State the specific exception category from the seven above. Document evidence (prior fills, contraindication, etc.).

Paragraph 4 — Clinical risk of delay

Continued obesity, worsening of comorbidities, cardiovascular event risk, mental health impact.

Paragraph 5 — Direct request

“I respectfully request approval of Wegovy at the prescribed dose with [#] months of authorization.”

Quick-reference appeal timeline
Appeal step	Typical timeline
Internal appeal (pre-service)	30 days
Internal appeal (post-service)	60 days
Internal appeal (urgent)	72 hours
Peer-to-peer review	Often 7–14 days from request
External review (standard)	45 days
External review (expedited)	72 hours
State DOI complaint	Varies by state and complaint type

A redditor on r/WegovyWeightLoss described their successful appeal as “understanding their own policies better than they did.” The pattern across successful appeals: read the insurer's medical policy line by line, quote it back, and show how your situation maps to coverage criteria.

If your prescriber's office won't handle the paperwork, Ro will.

Ro's insurance concierge contacts your plan and handles GLP-1 paperwork after you start care. Membership starts at $39 for the first month, then as low as $74/month with annual prepay ($149/month standard). Medication is billed separately.

Check Wegovy Coverage Through Ro →

No payment to run benefits. Medication and membership billed separately if you continue with Ro.

What if Your Plan Excludes Wegovy Entirely?

A benefit exclusion means your plan does not cover weight-loss medications at all — no amount of step therapy paperwork will fix it. Your real options are: check whether a different FDA-approved indication gets you covered, advocate for benefit changes through HR, or use a self-pay path while you sort out long-term coverage.

The cardiovascular indication path

Wegovy is FDA-approved to reduce major cardiovascular events (heart attack, stroke, cardiovascular death) in adults with established cardiovascular disease and either obesity or overweight. The SELECT trial in 17,604 patients showed a 20% reduction in major adverse cardiovascular events compared to placebo.

If you have a prior heart attack, prior stroke (not a TIA), documented peripheral arterial disease, or established CV disease — and obesity or overweight — ask your prescriber whether the PA should be submitted under the cardiovascular risk reduction indication when your chart supports it.

The MASH indication path

In August 2025, the FDA approved Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis. If you have documented MASH with fibrosis and a hepatologist or gastroenterologist involved in your care, your plan may cover under this indication.

The HR conversation

If you have a self-funded employer plan with weight-loss exclusion, the path runs through HR, not the insurance carrier. The employer plan sponsor may control the benefit design even when the insurer administers it.

Ask HR for the Summary Plan Description (SPD) and current formulary
Bring evidence of clinical need and demand from coworkers
Ask whether GLP-1 weight-loss coverage is on the open enrollment table
Push during the next annual benefits review

FDA-approved Wegovy self-pay options (as of May 4, 2026)

Option	Price	Notes
Wegovy pen via NovoCare	$199/mo for first 2 fills, then $349/mo	Intro offer through June 30, 2026 (0.25 mg or 0.5 mg starting doses)
Wegovy HD 7.2 mg pen	$399/mo	Via NovoCare
Wegovy pill (1.5 mg / 4 mg)	$149/mo (4 mg → $199/mo after Aug 31, 2026)	Through August 31, 2026
Wegovy pill (9 mg / 25 mg)	$299/mo	Via NovoCare

You can start on self-pay and continue the insurance fight on a parallel track. If your appeal succeeds, you switch to insurance-covered fills. Treatment progress doesn't reset. See our best telehealth for Wegovy guide for a full breakdown of self-pay paths.

How Long Does the Step Therapy Process Take?

A first prior authorization decision usually takes 1–7 business days when documentation is complete. If you can't wait, parallel cash-pay through Ro or NovoCare lets you start treatment while the paperwork plays out.

Step	Realistic timeline	What slows it down
Benefits verification	Same day to 3 days	Wrong PBM, outdated formulary
First PA submission	1–14 days	Missing BMI, comorbidity, or program records
Step therapy exception decision	72 hours (reform state) to 14 days	Inadequate exception documentation
Internal appeal decision	15–30 days	Vague appeal letter
Peer-to-peer review	7–14 days from request	Scheduling between prescriber and medical director
External review (standard)	45 days	Independent reviewer queue
External review (expedited)	72 hours	Medical urgency must be documented
Pharmacy fill after approval	1–7 days	Stock + dose availability

Your 7-Day Wegovy Step Therapy Action Sprint

Day 1:Pull every pharmacy fill record from the last 5 years. Read the denial letter twice. Identify which of the six rules your plan really wants.

Day 2:Call the insurer's pharmacy benefit number on your card. Get the exact PA criteria document and the specific denial reason. Take notes — names, reference numbers, dates.

Day 3:Match your situation to the right path: medication exception, lifestyle program documentation, BMI/comorbidity coding fix, renewal threshold, or benefit exclusion.

Day 4:Schedule with your prescriber. Bring the denial letter, your fill history, and the checklist from this page.

Days 5–6:Your prescriber submits the right document — Step Therapy Exception Request, formulary exception, appeal, or new PA with corrected documentation.

Day 7:If the timeline will be more than 30 days and you want to start now, check parallel self-pay through Ro or NovoCare while the appeal plays out.

Document Checklist for Your Prescriber

The single most common reason Wegovy step therapy denials don't get reversed is incomplete documentation — and the patient doesn't know what the doctor needs.

What to bring to your appointment

✓Original denial letter (paper or screenshot)
✓Insurance card (front and back)
✓Pharmacy benefit card if separate
✓Current weight, height, and BMI
✓Baseline weight before any weight-loss intervention
✓List of comorbidities and dates of diagnosis
✓Pharmacy fill history (last 5 years)
✓Weight-management program records (dietitian, gym, structured program receipts, logs)
✓Previous weight-loss medications: drug, dates, doses, duration, why stopped
✓Any documented contraindications or adverse reactions
✓Recent labs if available (A1c, lipid panel, BMP)

What your prescriber needs to write

✓Diagnosis section: ICD-10 codes, BMI documentation
✓Indication section: which FDA-approved Wegovy indication and supporting documentation
✓Lifestyle modification section: documented program participation
✓Medication history section: previous trials with dates, doses, durations, outcomes
✓Exception rationale section: which of the seven categories applies and why
✓Clinical risk section: what happens if treatment is delayed
✓Direct request section: specific medication, dose, duration of approval requested

When (and When Not) to Use a Telehealth Provider

A telehealth provider is worth the money when your bottleneck is paperwork and your current doctor's office won't handle it. It's not worth the money if your current prescriber is actively appealing well, your plan has a hard benefit exclusion no provider can fix, or you have specialty medical needs requiring in-person care.

When a telehealth provider helps

Your current prescriber's office refuses to handle prior authorizations
You don't have a current weight-loss prescriber and need one fast
You want one place to handle prescribing AND insurance paperwork
You want to start parallel self-pay while your appeal runs

When a telehealth provider can't help

Your plan has a hard benefit exclusion (no provider can override your employer's plan design)
Your current doctor is actively appealing well
You need specialty in-person care for safety reasons

Feature	Ro	Sesame Care
Free coverage check before commitment	Yes — GLP-1 Insurance Coverage Checker contacts your plan and identifies eligibility details; doesn't submit treatment requests or write prescriptions	Pay-per-visit model; no separate free coverage check on the public site at time of review
Insurance paperwork support	Yes — Ro's insurance concierge works with insurance and handles paperwork for GLP-1 coverage after a patient starts care	Providers can assist with insurance paperwork; not a centralized concierge team
Membership / platform price	$39 first month, then as low as $74/month with annual prepay ($149/month standard)	Success by Sesame as low as $59/month annually
FDA-approved Wegovy access	Yes — Wegovy pen and Wegovy pill	Yes — Wegovy pen, plus Zepbound, Ozempic, Mounjaro, Foundayo, Saxenda
Other FDA-approved GLP-1s	Zepbound, Zepbound KwikPen, Foundayo, Ozempic	Broad branded formulary including all major GLP-1s
Government insurance (Medicare/Medicaid/TRICARE)	Ro says it can't help coordinate GLP-1 coverage for government insurance plans	Verify current government-plan restrictions
Last verified	May 4, 2026	May 4, 2026

Ro — when it's the right pick

Ro's GLP-1 Insurance Coverage Checker provides a free benefits review. Ro's insurance concierge contacts your plan and handles GLP-1 paperwork after you start care. Membership starts at $39 first month, then $149/month standard (as low as $74/month with annual prepay). Wegovy pen self-pay via Ro/NovoCare starts at $199/month (intro pricing for first 2 monthly fills through June 30, 2026), then $349/month. Wegovy pill starts at $149/month for 1.5 mg and 4 mg through August 31, 2026.

The honest tradeoff: Ro is not the cheapest telehealth path. But if your bottleneck is paperwork your doctor's office won't handle, Ro's insurance concierge is doing the exact work you're stuck on. The membership often pays for itself in a single covered fill (Wegovy lists at $1,349.02/month before insurance discounts).

Check Wegovy Coverage Through Ro →

No payment to run benefits. Medication and membership billed separately.

Sesame Care — when it's the right pick

Lower monthly platform fees than Ro. Provider choice (you pick from a list of clinicians). Pay-as-you-go visit options. Success program includes ongoing care, labs, messaging, and access to FDA-approved GLP-1 medications. Providers can assist with insurance paperwork, though workflow is provider-by-provider rather than a centralized concierge.

When to pick Sesame over Ro: you want lower monthly cost, you want to choose your specific provider, you have a clear-cut insurance situation or are paying cash, you don't need white-glove paperwork management.

See Sesame Care's GLP-1 Options →

Medication not included in care fee. Billed separately.

If you have Medicare, Medicaid, or TRICARE: your path runs through your existing provider plus the rules of your specific government plan. Ro publicly says it can't help coordinate GLP-1 coverage for government insurance plans. Read our Medicare Wegovy guide for the government-plan-specific path including the Medicare GLP-1 Bridge program.

Safety and Medical Limits While Fighting Your Denial

Insurance rules don't decide whether Wegovy is medically right for you.

Wegovy carries a boxed warning related to thyroid C-cell tumors and is contraindicated in people with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. The FDA prescribing information also lists serious warnings for pancreatitis, gallbladder disease, kidney injury, severe hypoglycemia in patients with type 2 diabetes, and others.

⚠Don't start a step medication just to satisfy insurance if it's medically inappropriate for you. Document the contraindication with your prescriber instead.
⚠Don't combine Wegovy with another semaglutide product (Ozempic, Rybelsus) or any other GLP-1 receptor agonist (Trulicity, Saxenda, Mounjaro/Zepbound). BCBS FEP's public criteria explicitly require no dual GLP-1 therapy and no dual PA weight-loss medication.
⚠Don't share Wegovy pens or split doses without prescriber direction.
⚠If you're pregnant, planning to be pregnant, or breastfeeding, discuss with your prescriber. Wegovy is generally not recommended during pregnancy.

This page is editorial guidance about insurance process. It is not medical advice. Your prescriber's clinical judgment governs whether Wegovy is right for you.

What We Actually Verified for This Guide

Last verified: May 4, 2026 · Next planned re-verification: August 4, 2026.

Insurer and PBM policies verified:

✅Cigna Coverage Policy IP0206 (Weight Loss GLP-1 Agonists)
✅Cigna National Formulary Coverage Policy CNF_684
✅UnitedHealthcare PA Notification (Weight Loss Medications, commercial)
✅UnitedHealthcare PA Notification (Non-Formulary Wegovy CV/MASH-only)
✅BCBS FEP criteria via CVS Caremark
✅TRICARE / Express Scripts Wegovy PA form (current public version)

Clinical and regulatory sources verified:

✅FDA prescribing information for Wegovy injection and Wegovy tablets
✅FDA Wegovy MASH approval (August 2025)
✅SELECT trial cardiovascular outcomes data (NEJM)
✅STEP 1 trial weight-loss efficacy data (NEJM)
✅CMS consumer appeals materials and Medicare GLP-1 Bridge
✅KFF analysis of 2024 ACA Marketplace claims and appeals
✅State step therapy reform laws (NY, NJ, CA, CO, TX, IL, NM, WA and others)

What we did not verify and you must check yourself:

Your specific employer plan's customized formulary and any self-funded carve-outs
Your specific state Medicaid GLP-1 coverage policy
Your prescriber's individual willingness to file step therapy exception requests
Whether a step medication is medically appropriate for your specific health history
Whether your plan is fully insured or self-funded (ask HR)

Frequently Asked Questions

Does CVS Caremark require step therapy for Wegovy?+

Generally no on most CVS Caremark template formularies. CVS Caremark announced Wegovy as the preferred GLP-1 medicine for obesity on its largest commercial template formularies effective July 1, 2025. Most Aetna and CVS-administered BCBS plans on those template formularies skip cheaper-drug step therapy and require only standard prior authorization with 6-month weight-management program documentation. Self-funded employer plans on CVS Caremark may have customized formularies that still impose step therapy — confirm with HR.

Does Aetna require step therapy for Wegovy?+

Most fully-insured Aetna plans do not require true cheaper-drug fail-first because Aetna uses CVS Caremark as its PBM. Aetna's public Policy 4774-C (P08-2025 v4) requires a 6-month comprehensive weight-management program plus BMI/comorbidity documentation. Self-funded Aetna plans may have layered step therapy. The most common Aetna denial labeled 'step therapy' is actually missing program documentation.

Does Cigna require step therapy for Wegovy?+

Cigna's public Coverage Policy IP0206 requires 3 months of behavioral modification and dietary restriction for adult weight-loss approval, plus BMI ≥30 or ≥27 with comorbidity. The public criteria do not list a true cheaper-drug fail-first for Wegovy in the section reviewed, but self-funded plans on Cigna can elect step therapy. Verify your specific plan formulary.

Does UnitedHealthcare require step therapy for Wegovy?+

It depends on which UHC policy applies. Plans that elected weight-loss coverage follow a PA notification policy that includes Wegovy and other anti-obesity medications — initial auth is 5 months. Plans that exclude weight loss follow the non-formulary policy that allows Wegovy only for cardiovascular risk reduction or MASH. UHC also tends toward stricter BMI thresholds (BMI ≥40 in some plans).

Does BCBS require step therapy for Wegovy?+

It depends on which Blue plan. BCBS is 33+ independent locally-operated companies and policies vary dramatically. The BCBS Federal Employee Program criteria (administered through CVS Caremark) require a comprehensive weight-management program, BMI/comorbidity proof, no dual GLP-1 therapy, and no dual PA weight-loss medication — but no cheaper-drug fail-first in the public criteria.

Does TRICARE require step therapy for Wegovy?+

Yes for TRICARE Prime and Select. TRICARE's Express Scripts Wegovy PA form explicitly asks whether the adult patient tried 3 months of generic phentermine, benzphetamine, diethylpropion, or phendimetrazine and failed to lose 5% baseline weight, OR whether the patient has a contraindication or adverse reaction documented. TRICARE no longer covers GLP-1 medications for weight management for TRICARE For Life, direct-care-only beneficiaries, and certain NATO/Partnership for Peace beneficiaries after August 31, 2025.

Does Ozempic count as step therapy for Wegovy?+

Sometimes — it depends on your plan's criteria. Ozempic and Wegovy contain the same active ingredient (semaglutide), and many plans use documented prior Ozempic use as supporting documentation in a step therapy exception request. Whether it automatically satisfies step therapy depends on whether your plan's criteria specifically accept prior semaglutide or GLP-1 use. Pull your fill history regardless and have your prescriber include it.

Can I appeal a Wegovy step therapy denial?+

Yes. You typically have 180 days from the denial letter to file an internal appeal. KFF's 2024 ACA Marketplace data found fewer than 1% of denied in-network claims were appealed, while insurers upheld 66% of internal appeals (meaning roughly 1 in 3 internal appeals succeeded). For Medicare Advantage prior-authorization appeals, federal data shows about 80% of appealed PA denials were overturned. Appealing is worth the effort even though most patients don't try.

Can my doctor override step therapy for Wegovy?+

Your doctor cannot unilaterally override your insurer's step therapy requirement, but they can file a Step Therapy Exception Request citing one of seven recognized reasons: prior failure, contraindication, intolerance, expected adverse reaction, expected non-response, current stability on Wegovy, or clinical evidence the step drug isn't in your best interest. Federal Medicare Advantage rules require a 72-hour response. Most state reform laws require similar timelines for state-regulated commercial plans.

How long is the step therapy trial for Wegovy?+

Most commercial insurers that require step therapy require a 3-month trial of one preferred medication. Some plans require 6 months of supervised lifestyle modification on top of any medication trial. TRICARE's public form asks for a 3-month stimulant-class trial. Your specific plan's policy controls.

What if I cannot wait 3 months for step therapy?+

Two options. First: file a Step Therapy Exception Request (72-hour decision under federal MA rules and most state reform laws). Second: start parallel cash-pay through Ro or NovoCare while your appeal plays out — Wegovy pen self-pay starts at $199/month (intro pricing for the first 2 monthly fills through June 30, 2026) or the pill starts at $149/month for 1.5 mg and 4 mg through August 31, 2026. You don't have to choose one path; many readers do both.

What if my plan excludes Wegovy entirely?+

A benefit exclusion is different from step therapy and step therapy paperwork won't fix it. Three real options: ask whether a different FDA-approved indication applies (cardiovascular risk reduction or MASH), advocate for benefit changes through HR (especially for self-funded employer plans), or use a self-pay path through NovoCare or Ro while you sort out long-term coverage.

Is Wegovy covered by Medicare?+

Wegovy is covered under Medicare Part D only when prescribed for a medically accepted non-weight-loss indication (such as cardiovascular risk reduction in adults with established cardiovascular disease and overweight or obesity). It is not covered for weight loss alone. CMS announced the Medicare GLP-1 Bridge, scheduled to provide eligible Part D beneficiaries access to certain GLP-1 drugs for weight reduction from July 1, 2026 through December 31, 2027.

What's the fastest legitimate way to get Wegovy approved?+

If you have prior GLP-1 use (Ozempic, Saxenda, etc.), document it and have your prescriber submit it with the first PA. If you have established cardiovascular disease, ask your prescriber whether the prescription should be submitted under the CV risk reduction indication when your chart supports it. If neither applies and your plan requires true step therapy, file a Step Therapy Exception Request with a documented contraindication or prior failure if one exists. If you can't wait, start parallel self-pay while the paperwork runs.

Still Not Sure Which Path Is Right for You?

Your situation is one of six things — usually documentation, sometimes a true medication trial, sometimes a benefit exclusion that no paperwork solves. The next move depends on which one. Take 60 seconds to find your path.

Take the Free 60-Second Matching Quiz →Check Coverage Through Ro →

No commitment. The free coverage checker doesn't prescribe medication or submit treatment requests.